# Suzanne L. Topalian

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/suzanne-l-topalian/

## Facts

| Field | Value |
| --- | --- |
| Citations | 98,037 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 101 |
| i10-index | 213 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5052980036 |
| ORCID iD | https://orcid.org/0000-0002-0821-8587 |
| Works | 360 |

## Researcher papers

Showing 12 of 16.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates](https://scholariq.org/papers/phase-i-study-of-single-agent-anti-programmed-death-1-mdx-1106-in-refractory/)
- [Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes](https://scholariq.org/papers/cancer-regression-and-autoimmunity-in-patients-after-clonal-repopulation-with/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma](https://scholariq.org/papers/use-of-tumor-infiltrating-lymphocytes-and-interleukin-2-in-the-immunotherapy-of/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma](https://scholariq.org/papers/cancer-regression-and-autoimmunity-induced-by-cytotoxic-t-lymphocyte-associated/)
- [Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.](https://scholariq.org/papers/randomized-prospective-study-of-the-benefit-of-adjuvant-radiation-therapy-in-the/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.